search
Back to results

High-intensity Interval Training Prescriptions to Reduce the Risk of Complications Linked to Type 2 Diabetes: the Role of Interval Length on Clinical Benefits and on Physiological Mechanisms

Primary Purpose

Diabetes Mellitus, Type 2

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
High-intensity interval training (HIIT)-4
High-intensity interval training (HIIT)-10
Rest
Sponsored by
Université de Sherbrooke
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus, Type 2 focused on measuring Type 2 diabetes, Ambulatory blood pressure, Continous glucose monitoring, High-intensity interval training, Proteomics, Monocytes, Inflammation

Eligibility Criteria

60 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • With a diagnostic for type 2 diabetes
  • Arterial hypertension (controlled at rest)
  • Low or no alcohol consumption (≤ 7 alcoholic beverages/week)
  • Non-smoking
  • Physically active ( > 60 minutes of structured and scheduled physical activity/week for the previous 3 months)

Exclusion Criteria:

  • Insulin therapy
  • Use of beta blockers
  • Unstable medication in the past 6 months
  • Stroke in the past 6 months, or with consequences limiting physical activity practice
  • Coronary disease without revascularization, or peripheral artery disease
  • Neuropathy, retinopathy of nephropathy diagnostics
  • Orthopedic limitations, or medical counter-indication for physical activity practice
  • Surgery scheduled during the study period

Sites / Locations

  • Centre de recherche sur le vieillissementRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Rest, HIIT-4, HIIT-10

Rest, HIIT-10, HIIT-4

Arm Description

Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random. This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10.

Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random. This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4.

Outcomes

Primary Outcome Measures

Change in ambulatory systolic and diastolic blood pressure
mmHg, measured with an ambulatory blood pressure monitor

Secondary Outcome Measures

Change in arterial stiffness
Estimated using pulse wave velocity (m/s), measured with an ambulatory blood pressure monitor
Change in post-exercise glucose levels
Measured with a continuous glucose monitor (mmol/L)
Change in post-prandial glucose levels
Measured with a continuous glucose monitor and blood samples (mmol/L)
Change in 24h glycemia
Measured with a continuous glucose monitor (mmol/L)
Change in nocturnal glycemia
Measured with a continuous glucose monitor (mmol/L)
Change in time passed in hyperglycemia (> 10 mmol/L)
Measured with a continuous glucose monitor (minutes)
Change in time passed in hypoglycemia (< 3.8 mmol/L)
Measured with a continuous glucose monitor (minutes)
Change in time spent in range (between 3.8 and 10 mmol/L)
Measured with a continuous glucose monitor (minutes)
Change in the proteome of blood monocytes
Use of proteomics to identify and quantify proteins in isolated peripheral blood monocytes
Change in the proportions of blood monocytes subtypes
Surface expression of CD14 and CD16, assessed by flow cytometry on isolated monocytes.
Resting systolic and diastolic blood pressure
Measured with a manual sphygmomanometer
Total body weight
Measured with an electric scale (kg)
Height
Measured with an mural stadiometer (m)
Change in monocyte-derived macrophages polarization
Surface expression of CD86 and CD206, assessed by flow cytometry on monocyte-derived macrophages differentiated 5 days in vitro.
Change in monocyte-derived macrophages response to lipopolysaccharide (LPS)
Monocyte-derived macrophages differentiated 5 days in vitro will be treated or not with LPS for 24h. Culture media will be collected for cytokine secretion determination (Multiplex Luminex)
Change in plasma endothelial nitric oxide synthase (eNOS)
Enzyme-Linked Immunosorbent Assay (ELISA) to quantify the level of human eNOS in plasma (ng/mL).
Change in plasma catecholamines
Enzyme-Linked Immunosorbent Assay (ELISA) to quantify the level of human epinephrine and norepinephrine in plasma (pg/mL).
Change in plasma insulin
Dosage of plasma insulin (pmol/L)
Change in plasma C-peptide
Dosage of plasma C-peptide (ng/mL)

Full Information

First Posted
July 7, 2021
Last Updated
March 29, 2023
Sponsor
Université de Sherbrooke
search

1. Study Identification

Unique Protocol Identification Number
NCT04986345
Brief Title
High-intensity Interval Training Prescriptions to Reduce the Risk of Complications Linked to Type 2 Diabetes: the Role of Interval Length on Clinical Benefits and on Physiological Mechanisms
Official Title
High-intensity Interval Training Prescriptions to Reduce the Risk of Complications Linked to Type 2 Diabetes: the Role of Interval Length on Clinical Benefits and on Physiological Mechanisms
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 4, 2021 (Actual)
Primary Completion Date
May 15, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Université de Sherbrooke

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes (T2D) prevalence has steadily been rising in the past decades and its complications, including cardiovascular diseases (CVD), are a major public health concern. To lower CVD risk and to maintain an adequate glycemic control, Diabetes Canada recommends aerobic exercise of high-intensity interval training (HIIT). The leading hypothesis of this study is that longer intervals will favor an anti-inflammatory immune state, and that and that it will be correlated with reduced arterial stiffness and blood pressure.
Detailed Description
Type 2 diabetes (T2D) prevalence has steadily been rising in the past decades and its complications, including cardiovascular diseases (CVD), are a major public health concern. Insulin resistance, an important component of T2D, is associated with vascular dysfunctions, which directly contributes to the pathogenesis of CVD, such as atherosclerosis, and hypertension, particularly with the elderly. It is also suggested that glucose variability, measured with continuous glucose monitors (CGM), is an independent risk factor of CVD in T2D individuals, exposing them to an increased risk of premature death. Moreover, in part because of immune dysregulation, women with T2D are at a heightened risk of developing CVD compared to males. Indeed, monocyte inflammatory profile is altered during the aging process and in women with T2D. This, in turn, causes vascular dysfunction which is associated with a pro-thrombotic state, and exacerbates atherosclerosis and arterial stiffening. To lower CVD risk and to maintain an adequate glycemic control, Diabetes Canada recommends aerobic exercise of high-intensity interval training (HIIT). However, this recommendation is solely based on the improvement of cardiorespiratory fitness in type 2 diabetes individuals (level of evidence: grade B, level 2). Furthermore, most of these studies use exercise protocols with ergocycles, which limit the ecological validity considering that the elderly population prefers to walk. Though, it is essential to evaluate the impact of different walking HIIT protocols on clinical targets such as arterial pressure, glycemic variability/control using ambulatory blood pressure monitors (ABPM) and CGM. The preliminary data collected in our laboratory shows that a low volume HIIIT program (6 × 1 min) is insufficient to improve glycemic control/variability and ambulatory blood pressure over 24 hours in elderly diabetic women, despite reducing inflammatory gene expression in monocytes. Interestingly, pro-inflammatory monocytes are linked with hyperglycemia and play a crucial role in the atherosclerotic process, while also being associated with arterial stiffening in individuals with kidney failure, a common T2D complication. These results raise several questions, including the role played by the length of HIIT intervals on clinical targets. While our preliminary results didn't impact ambulatory blood pressure over 24 hours with shorter intervals (6 × 1 min), other studied showed a reduction of this parameter with longer intervals (4 x 4 min). Therefore, the leading hypothesis of this study is that longer high intensity intervals (Wisløff protocol: 4 x 4 min) will reduce ambulatory blood pressure over 24 hours in a greater extent than shorter intervals (10 x 1 min). Indeed, reduced shear stress induced by shorter intervals could damper cellular and molecular responses to exercise bouts, thereby limiting the effects on arterial stiffness and blood pressure in the hours following exercise. Moreover, changes in gene expression do not guarantee changes at the protein level, and proteins are the real effectors of cellular response. Hence, proteomics will be useful to better understand monocyte response to different HIIT protocols and, possibly, the clinical benefits of this training method. Indeed, longer intervals could induce greater variations to the monocytes' proteome, favoring an anti-inflammatory phenotype, and those changes could be associated with reduced arterial stiffness and blood pressure. The primary objective of this study is therefore to compare the effect of two treadmill HIIT modalities (4x4 min vs. 10x1 min) on arterial stiffness, ambulatory blood pressure over 24 hours and on glycemic variability in elderly women with T2D. The secondary objective is to assess the proteomic changes in monocytes induced by the two HIIT modalities and to correlate them with changes in clinical parameters.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Type 2 diabetes, Ambulatory blood pressure, Continous glucose monitoring, High-intensity interval training, Proteomics, Monocytes, Inflammation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
A semi-randomized (experimental conditions) crossover design will be used with a population of elderly women with T2D, and with three experimental conditions (1- rest, 2-HIIT-10: 10x 1 min, 3- HIIT-4: 4 x 4 min).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Rest, HIIT-4, HIIT-10
Arm Type
Experimental
Arm Description
Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random. This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10.
Arm Title
Rest, HIIT-10, HIIT-4
Arm Type
Experimental
Arm Description
Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random. This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4.
Intervention Type
Other
Intervention Name(s)
High-intensity interval training (HIIT)-4
Intervention Description
4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.
Intervention Type
Other
Intervention Name(s)
High-intensity interval training (HIIT)-10
Intervention Description
10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.
Intervention Type
Other
Intervention Name(s)
Rest
Intervention Description
Participants are to stay seated for 30 minutes while reading or watching television.
Primary Outcome Measure Information:
Title
Change in ambulatory systolic and diastolic blood pressure
Description
mmHg, measured with an ambulatory blood pressure monitor
Time Frame
During 24 hours after the three experimental conditions (Rest, HIIT-4 and HIIT-10)
Secondary Outcome Measure Information:
Title
Change in arterial stiffness
Description
Estimated using pulse wave velocity (m/s), measured with an ambulatory blood pressure monitor
Time Frame
30 min post-exercise (in lab measure) and during 24 hours after the three experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in post-exercise glucose levels
Description
Measured with a continuous glucose monitor (mmol/L)
Time Frame
Every 5 min during 2 hours after each experimental condition (Rest, HIIT-4 and HIIT-10)
Title
Change in post-prandial glucose levels
Description
Measured with a continuous glucose monitor and blood samples (mmol/L)
Time Frame
during the 2 hour-postprandial time (before and after standardized lunch, as well as at 7.5 , 15, 30 60, 90 and 120 min) for each experimental condition (Rest, HIIT-4, HIIT-10)
Title
Change in 24h glycemia
Description
Measured with a continuous glucose monitor (mmol/L)
Time Frame
During 24 hours after the three experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in nocturnal glycemia
Description
Measured with a continuous glucose monitor (mmol/L)
Time Frame
During the night, from 10 pm to 7 am following each the three experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in time passed in hyperglycemia (> 10 mmol/L)
Description
Measured with a continuous glucose monitor (minutes)
Time Frame
During 24 hours after each experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in time passed in hypoglycemia (< 3.8 mmol/L)
Description
Measured with a continuous glucose monitor (minutes)
Time Frame
During 24 hours after each experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in time spent in range (between 3.8 and 10 mmol/L)
Description
Measured with a continuous glucose monitor (minutes)
Time Frame
During 24 hours after each experimental conditions (Rest, HIIT-4 and HIIT-10)
Title
Change in the proteome of blood monocytes
Description
Use of proteomics to identify and quantify proteins in isolated peripheral blood monocytes
Time Frame
Before, right after the end and 1hour post exercise (HIIT-4 and HIIT-10)
Title
Change in the proportions of blood monocytes subtypes
Description
Surface expression of CD14 and CD16, assessed by flow cytometry on isolated monocytes.
Time Frame
Before, right after the end and 1hour post exercise (HIIT-4 and HIIT-10)
Title
Resting systolic and diastolic blood pressure
Description
Measured with a manual sphygmomanometer
Time Frame
During the preliminary visit, after 5 min of rest in sitting position
Title
Total body weight
Description
Measured with an electric scale (kg)
Time Frame
At baseline, in fasted state
Title
Height
Description
Measured with an mural stadiometer (m)
Time Frame
At baseline, in fasted state
Title
Change in monocyte-derived macrophages polarization
Description
Surface expression of CD86 and CD206, assessed by flow cytometry on monocyte-derived macrophages differentiated 5 days in vitro.
Time Frame
Before and right after the end of exercise (HIIT-4 and HIIT-10)
Title
Change in monocyte-derived macrophages response to lipopolysaccharide (LPS)
Description
Monocyte-derived macrophages differentiated 5 days in vitro will be treated or not with LPS for 24h. Culture media will be collected for cytokine secretion determination (Multiplex Luminex)
Time Frame
Before and right after the end of exercise conditions (HIIT-4 and HIIT-10)
Title
Change in plasma endothelial nitric oxide synthase (eNOS)
Description
Enzyme-Linked Immunosorbent Assay (ELISA) to quantify the level of human eNOS in plasma (ng/mL).
Time Frame
Before, at the end of exercise and 1 hour post-exercise (HIIT-4 and HIIT-10)
Title
Change in plasma catecholamines
Description
Enzyme-Linked Immunosorbent Assay (ELISA) to quantify the level of human epinephrine and norepinephrine in plasma (pg/mL).
Time Frame
Before, at the end of exercise and 1 hour post-exercise (HIIT-4 and HIIT-10)
Title
Change in plasma insulin
Description
Dosage of plasma insulin (pmol/L)
Time Frame
during the 2 hour-postprandial time (before and after standardized lunch, as well as at 7.5, 15, 30 60, 90 and 120 min) for each experimental condition (Rest, HIIT-4, HIIT-10)
Title
Change in plasma C-peptide
Description
Dosage of plasma C-peptide (ng/mL)
Time Frame
during the 2 hour-postprandial time (before and after standardized lunch, as well as at 7.5, 15, 30 60, 90 and 120 min) for each experimental condition (Rest, HIIT-4, HIIT-10)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: With a diagnostic for type 2 diabetes Arterial hypertension (controlled at rest) Low or no alcohol consumption (≤ 7 alcoholic beverages/week) Non-smoking Physically active ( > 60 minutes of structured and scheduled physical activity/week for the previous 3 months) Exclusion Criteria: Insulin therapy Use of beta blockers Unstable medication in the past 6 months Stroke in the past 6 months, or with consequences limiting physical activity practice Coronary disease without revascularization, or peripheral artery disease Neuropathy, retinopathy of nephropathy diagnostics Orthopedic limitations, or medical counter-indication for physical activity practice Surgery scheduled during the study period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eléonor Riesco, PhD
Phone
1-819-821-8000
Ext
63337
Email
e.riesco@usherbrooke.ca
Facility Information:
Facility Name
Centre de recherche sur le vieillissement
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 4C4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eléonor Riesco, PhD
Phone
1-819-821-8000
Ext
63337
Email
eleonore.riesco@usherbrooke.ca
First Name & Middle Initial & Last Name & Degree
Eléonor Riesco, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30170598
Citation
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 31;17(1):122. doi: 10.1186/s12933-018-0762-4.
Results Reference
background
PubMed Identifier
20380649
Citation
Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010 Apr;12(4):288-98. doi: 10.1111/j.1463-1326.2009.01160.x.
Results Reference
background
PubMed Identifier
15560901
Citation
Shalev V, Chodick G, Heymann AD, Kokia E. Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health. 2005 Jan;119(1):45-9. doi: 10.1016/j.puhe.2004.03.004.
Results Reference
background
PubMed Identifier
26029318
Citation
Peters SA, Huxley RR, Sattar N, Woodward M. Sex Differences in the Excess Risk of Cardiovascular Diseases Associated with Type 2 Diabetes: Potential Explanations and Clinical Implications. Curr Cardiovasc Risk Rep. 2015;9(7):36. doi: 10.1007/s12170-015-0462-5.
Results Reference
background
PubMed Identifier
29650112
Citation
Diabetes Canada Clinical Practice Guidelines Expert Committee; Sigal RJ, Armstrong MJ, Bacon SL, Boule NG, Dasgupta K, Kenny GP, Riddell MC. Physical Activity and Diabetes. Can J Diabetes. 2018 Apr;42 Suppl 1:S54-S63. doi: 10.1016/j.jcjd.2017.10.008. No abstract available.
Results Reference
background
PubMed Identifier
29283793
Citation
Amireault S, Baier JM, Spencer JR. Physical Activity Preferences Among Older Adults: A Systematic Review. J Aging Phys Act. 2018 Oct 25:1-12. doi: 10.1123/japa.2017-0234. Online ahead of print.
Results Reference
background
PubMed Identifier
12716761
Citation
Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003 May;52(5):1256-64. doi: 10.2337/diabetes.52.5.1256.
Results Reference
background
PubMed Identifier
32717023
Citation
Roy-Chowdhury E, Brauns N, Helmke A, Nordlohne J, Brasen JH, Schmitz J, Volkmann J, Fleig SV, Kusche-Vihrog K, Haller H, von Vietinghoff S. Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction. Cardiovasc Res. 2021 May 25;117(6):1510-1522. doi: 10.1093/cvr/cvaa234.
Results Reference
background
PubMed Identifier
26877933
Citation
Lee JW, Cho E, Kim MG, Jo SK, Cho WY, Kim HK. Proinflammatory CD14(+)CD16(+) monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease. Kidney Res Clin Pract. 2013 Dec;32(4):147-52. doi: 10.1016/j.krcp.2013.08.001. Epub 2013 Sep 26.
Results Reference
background
PubMed Identifier
28493030
Citation
Ramirez-Jimenez M, Morales-Palomo F, Pallares JG, Mora-Rodriguez R, Ortega JF. Ambulatory blood pressure response to a bout of HIIT in metabolic syndrome patients. Eur J Appl Physiol. 2017 Jul;117(7):1403-1411. doi: 10.1007/s00421-017-3631-z. Epub 2017 May 10.
Results Reference
background
PubMed Identifier
31565193
Citation
Ito S. High-intensity interval training for health benefits and care of cardiac diseases - The key to an efficient exercise protocol. World J Cardiol. 2019 Jul 26;11(7):171-188. doi: 10.4330/wjc.v11.i7.171.
Results Reference
background

Learn more about this trial

High-intensity Interval Training Prescriptions to Reduce the Risk of Complications Linked to Type 2 Diabetes: the Role of Interval Length on Clinical Benefits and on Physiological Mechanisms

We'll reach out to this number within 24 hrs